Last month, we introduced the topic of peptides and the role they are beginning to play in modern medicine. Given how quickly this space is evolving, I wanted to share a follow-up based on some recent time I spent at a conference with the American Academy of Anti-Aging Medicine (A4M) in Las Vegas.

Much of the discussion there centered around peptides — how they’re being used, what’s emerging, and how the regulatory landscape is shifting.

If you’ve been hearing more about peptides lately, you’re not alone. Interest has grown rapidly, and with that has come a mix of exciting potential and, at times, a lot of confusion. One of the biggest topics at the conference was the evolving FDA position on peptides.

Some compounds that had been in a regulatory gray zone are now being re-evaluated, with certain peptides being reviewed for potential use through compounding pharmacies, while others remain restricted due to safety concerns or lack of sufficient data. What’s important to understand is this:

Not all peptides are created equal — and not all are appropriate to use in clinical practice today.

There are a small number of peptide-based therapies that are well-studied, FDA-approved, and form the foundation of what we currently use. There are others that show promise but are still under review, and a third category that remains outside of what we would consider safe or appropriate to incorporate at this time.

This is where the conversation often gets oversimplified online. You’ll hear about peptides like BPC-157, TB-500, or newer compounds being discussed as if they’re widely available and ready for use. In reality, many of these are still being evaluated, and their regulatory status is actively evolving.

At the same time, there is another important trend that often goes unspoken. Because of these restrictions, many individuals have turned to purchasing peptides online, often labeled as “for research use only.”

This designation is not a marker of safety — it is a legal classification that allows these products to be sold without FDA oversight for human use.

These products are not regulated in the way prescription medications are, and that introduces several real risks:

• Inconsistent purity and potency – the dose listed may not reflect what is actually in the vial
• Contamination risks – including bacteria, endotoxins, or heavy metals
• Incorrect or substituted compounds – products may not contain what they claim
• Lack of sterility – especially concerning for injectable use
• No established dosing, safety, or long-term human data
• No medical oversight – meaning no guidance on appropriateness, interactions, or monitoring

This is one of the most important distinctions in this space.

Peptides used within a medical setting are selected, sourced, and monitored very differently than those obtained independently online.

What I took away most from this meeting wasn’t just what’s new — it was how important it is to be thoughtful about what we choose to bring into patient care.

Our approach remains consistent. We focus on therapies that are both clinically effective and appropriate today, while staying closely engaged with what’s coming next so we can integrate new options responsibly as the science and regulations evolve.

Peptides are an exciting area of medicine, and they will likely play an increasing role in how we approach metabolism, recovery, and longevity. But as with anything in medicine, the goal is not to use what’s new — it’s to use what works, safely, and in the right context for each individual.